Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...
Cancer
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...
Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...
China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs
The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...
AnchorDx Initiates US Registrational Study for UriFind Urothelial Carcinoma Diagnostic
China-based AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has announced the initiation...
Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano
Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...
Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...
JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston
Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...
Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening
Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...
IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...
Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...
Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging
Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...